Epstein-Barr Virus and Cancer Risks
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Diagnostic test: EBV antibody tests.
- Who it may be relevant to
- Registry conditions: Cancer. Basic parameters: 30 years — 69 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Prospective Cohort Study on Epstein-Barr Virus Antibody and Cancer Risks
Overview
The goal of this prospective cohort study is to investigate the associations between Epstein-Barr Virus (EBV) antibody levels and the risk of overall and site-specific cancer types in Southern China. The main questions it aims to answer are: Question 1: In addition to the established EBV-associated cancer types, such as lymphomas, nasopharyngeal carcinoma, and stomach cancer, whether EBV is associated with other cancer types? Question 2: What's the cancer burden attributed to EBV in Southern China?
Detailed description
Growing molecular evidence suggests the involvement of EBV in various cancers, however, comprehensive epidemiological evidence is still lacking. In this study, researchers conducted a population-based prospective cohort study to investigate the associations between EBV antibodies and the risk of overall and site-specific cancer types in Southern China. All the participants underwent EBV antibody tests at enrollment and were subsequently followed up annually for cancer incidence, vital status, and immigration status. The primary objective of this study was to provide prospective evidence for the role of EBV in multiple cancers, shedding light on the etiology of a broad range of common EBV-associated cancers.
Interventions
- Other Diagnostic test: EBV antibody tests
Participants underwent several EBV antibody tests, including VCA-IgA, EBNA1-IgA, etc.
Primary outcome measures
- Cancer incidence [Time frame: 10 years]
Secondary outcome measures (1)
- All-cause mortality [Time frame: 10 years]
Eligibility criteria
Inclusion criteria
- Subject residents in Zhongshan or Wuzhou City;
- Subject has no medical record of prevalent cancer;
- Subject has psychical condition and well consciousness, and willingness to accept and cooperate with the study\'s follow-up procedures.
Exclusion criteria
- Subject has heavy cardiovascular, liver, or kidney disease;
- Subject has prevalent cancer.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study locations
China · 2 centers
- Zhongshan People's Hospital — Zhongshan
- Wuzhou Red Cross Hospital — Wuzhou
Identifiers
NCT: NCT06203314 · EBV-PRO-001